Innoviva (INVA) Cash from Operations Growth (1y) (2011 - 2026)
Innoviva (INVA) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Innoviva |
1.65 Bn |
1.05 Bn |
75.83 Mn |
-27.43% |
| Date | Value |
|---|
| Mar 31, 2026 |
-27.43% |
| Sep 30, 2025 |
10.02% |
| Jun 30, 2025 |
0.81% |
| Mar 31, 2025 |
31.23% |
| Sep 30, 2024 |
20.08% |
| Jun 30, 2024 |
14.50% |
| Mar 31, 2024 |
44.24% |
| Sep 30, 2023 |
-44.09% |
| Jun 30, 2023 |
-51.69% |
| Mar 31, 2023 |
-73.82% |
| Sep 30, 2022 |
-27.35% |
| Jun 30, 2022 |
-6.59% |
| Mar 31, 2022 |
16.64% |
| Sep 30, 2021 |
256.01% |
| Jun 30, 2021 |
6.04% |
| Mar 31, 2021 |
14.46% |
| Dec 31, 2020 |
27.46% |
| Sep 30, 2020 |
29.89% |
| Jun 30, 2020 |
41.24% |
| Mar 31, 2020 |
-4.14% |
